Xponance Inc. Sells 904 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Posted by on Oct 3rd, 2023

Xponance Inc. reduced its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART – Free Report) by 9.4% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,695 shares of the life sciences company’s stock after selling 904 shares during the period. Xponance Inc.’s holdings in Integra LifeSciences were worth $358,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Global Retirement Partners LLC boosted its position in shares of Integra LifeSciences by 3,103.7% in the 1st quarter. Global Retirement Partners LLC now owns 865 shares of the life sciences company’s stock worth $44,000 after purchasing an additional 838 shares during the last quarter. Covestor Ltd lifted its holdings in Integra LifeSciences by 63.0% during the first quarter. Covestor Ltd now owns 1,558 shares of the life sciences company’s stock worth $100,000 after acquiring an additional 602 shares in the last quarter. Ronald Blue Trust Inc. lifted its holdings in Integra LifeSciences by 215.9% during the first quarter. Ronald Blue Trust Inc. now owns 2,025 shares of the life sciences company’s stock worth $113,000 after acquiring an additional 1,384 shares in the last quarter. Captrust Financial Advisors lifted its holdings in Integra LifeSciences by 95.0% during the first quarter. Captrust Financial Advisors now owns 2,003 shares of the life sciences company’s stock worth $129,000 after acquiring an additional 976 shares in the last quarter. Finally, Pearl River Capital LLC bought a new position in Integra LifeSciences during the first quarter worth about $201,000. 84.13% of the stock is currently owned by institutional investors.

Integra LifeSciences Price Performance

NASDAQ:IART opened at $38.01 on Tuesday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.85 and a current ratio of 2.78. The stock’s 50-day simple moving average is $41.83 and its 200 day simple moving average is $45.76. The company has a market cap of $3.09 billion, a P/E ratio of 24.21, a P/E/G ratio of 1.54 and a beta of 1.21. Integra LifeSciences Holdings Co. has a 52-week low of $37.36 and a 52-week high of $60.69.

Integra LifeSciences (NASDAQ:IART – Get Free Report) last released its earnings results on Wednesday, July 26th. The life sciences company reported $0.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.14. The business had revenue of $381.30 million for the quarter, compared to the consensus estimate of $388.79 million. Integra LifeSciences had a return on equity of 15.60% and a net margin of 8.49%. Integra LifeSciences’s quarterly revenue was down 4.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.82 earnings per share. As a group, sell-side analysts forecast that Integra LifeSciences Holdings Co. will post 3.14 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IART has been the topic of several recent analyst reports. StockNews.com upgraded Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Monday. JMP Securities reduced their target price on Integra LifeSciences from $65.00 to $60.00 and set an “outperform” rating on the stock in a report on Friday, July 28th. Jefferies Financial Group upgraded Integra LifeSciences from a “hold” rating to a “buy” rating and reduced their target price for the stock from $58.00 to $53.00 in a report on Wednesday, July 12th. Piper Sandler dropped their price target on Integra LifeSciences from $55.00 to $44.00 in a research note on Monday, June 26th. Finally, Argus downgraded Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Thursday, June 8th. Three analysts have rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $47.29.

Read Our Latest Research Report on IART

About Integra LifeSciences

(Free Report)

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

Read More

Institutional Ownership by Quarter for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.